{"id":"W4206062027","doi":"10.1016/j.ejca.2021.12.012","title":"Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Kingston Health Sciences Centre; Queen's University","funders":"Genentech; Servier; Cilag; Astellas Pharma; Incyte; Ipsen; Clovis Oncology; Strong; Sanofi; Exelixis; Eisai; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Clinical endpoint; Internal medicine; Adverse effect; Population; Urology; Tolerability; Phases of clinical research; Oncology; Surgery; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005820452,0.000224803,0.0006649434,0.0002257428,0.00006437041,0.00001405846,0.0003979456,0.00001364647,0.000137267],"category_scores_gemma":[0.00001501222,0.0001689459,0.00005212866,0.000278394,0.00004686305,0.0002626737,0.00009307571,0.0003264925,4.538971e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003299947,"about_ca_system_score_gemma":0.0003457179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000526498,"about_ca_topic_score_gemma":0.00003859306,"domain_scores_codex":[0.9969974,0.0008435242,0.0009963901,0.0002740678,0.0006671658,0.0002214798],"domain_scores_gemma":[0.9981697,0.00003027864,0.0009654948,0.0003744674,0.000293657,0.0001663987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1803814,0.0876236,0.6601731,0.0000775736,0.0006344749,0.001775822,0.008574901,0.0002648748,0.001340453,2.523743e-7,0.0002537586,0.05889973],"study_design_scores_gemma":[0.1951893,0.1190899,0.6834398,0.0001936929,0.0003262263,0.00003973344,0.0007784897,0.00002370047,0.000308378,2.796513e-7,0.0004888721,0.0001216136],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957308,0.001373046,0.000002035177,0.00005673178,0.0001187287,0.001506616,0.0002028431,0.000006461512,0.001002806],"genre_scores_gemma":[0.9992315,0.000122262,0.000139406,0.00009388568,0.00006603643,0.0000244467,0.00003203045,0.00006973513,0.0002207254],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05877812,"threshold_uncertainty_score":0.6889415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04576036169986496,"score_gpt":0.3418975716791859,"score_spread":0.2961372099793209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}